August 12, 2019 10:52 AM EDT

How does TDP-43 bog up the brains of ALS, FTLD patients? AC Immune enlists Penn scientists to find out

Amber Tong

AC Immune, the Swiss biotech known for its tau approach to Alzheimer’s, is shining light on another misfolding protein believed to be responsible for other …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

How does TDP-43 bog up the brains of ALS, FTLD patients? AC Immune enlists Penn scientists to find out

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

How does TDP-43 bog up the brains of ALS, FTLD pa­tients? AC Im­mune en­lists Penn sci­en­tists to find out

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

How does TDP-43 bog up the brains of ALS, FTLD patients? AC Immune enlists Penn scientists to find out

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data